aTyr Pharma, Inc. ATYR R2K
Healthcare · Biotechnology · United States
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
READ MORE ›$0.54
-87.85% 1Y
Market & Price
Market Cap
$53.19M
Current Price
$0.54
High / Low (52W)
$6.61 / $0.40
Beta
0.66
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$0.59
Price to Book
0.92
P/S
279.96
EV/EBITDA
0.03
Dividend Yield
-
Profitability & Returns
ROCE
-99.71%
ROE
-105.63%
ROA
-51.79%
Profit Margin
0.00%
Op Margin
-
EPS (Latest Qtr)
$-0.11
EPS (TTM)
$-0.74
Balance Sheet & Liquidity
Debt/Equity
0.20
Quick Ratio
5.73
Current Ratio
5.78
Debt
$11.70M
Total Assets
$93.00M
Current Assets
$80.24M
Working Capital
$65.09M
Ownership
Promoter Holding
2.45%
Chg in Prom Hold
0.00%
FII / Inst Holding
57.51%
Chg in FII Hold
0.00%
Financial Snapshot
Enterprise Value
$-1.81M
Total Revenue (TTM)
$190.00K
EBITDA
$-72.63M
Free Cash Flow
$-32.65M
Operating Cash Flow
$-59.08M
Shares Outstanding
98.05M
Gross Margin
0.00%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
-73.65%
Profit 5Y
-21.16%
Revenue (YoY)
-
Earnings (YoY)
-
PROS
No notable strengths flagged.
CONS
- Revenue declined at -73.7% CAGR over 5 years.
- Earnings shrank at -21.2% CAGR over 5 years.
- Trading 91.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ATYR aTyr Pharma, Inc. R2K | 0.54 | - | $53.19M | - | -99.71% | -105.63% | -73.65% | -21.16% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 94.00K | 184.00K | - | 8.06M | 189.00K | 148.00K | - | - | - | - | - | 0 | 0 | 0 | 353.00K | 235.00K | 0 | 0 | 0 | 0 | 190.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.77M | 20.31M | 26.93M | 14.80M | 11.44M |
| Operating Income | -8.92M | -10.90M | -11.31M | - | -16.11M | -15.43M | -13.87M | - | -13.21M | -11.91M | -10.83M | - | -10.22M | -9.96M | -6.68M | - | -5.88M | -5.64M | -5.50M | - | 1.86M | -6.32M | -6.51M | -7.20M | -10.45M | -7.73M | -12.38M | -12.58M | -13.49M | -12.79M | -13.56M | -12.62M | -16.64M | -17.32M | -18.14M | -15.77M | -20.31M | -26.75M | -14.80M | -11.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.39M | -19.93M | -26.36M | -14.40M | -11.04M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -14.88M | -19.53M | -25.75M | -13.96M | -10.79M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -9.07M | -11.08M | -11.33M | -16.49M | -16.09M | -15.38M | -13.82M | -12.57M | -13.40M | -12.14M | -11.19M | -11.47M | -10.67M | -10.41M | -7.11M | -6.32M | -6.14M | -5.85M | -5.64M | -5.97M | 1.75M | -6.45M | -6.60M | -7.15M | -10.39M | -7.67M | -12.15M | -12.42M | -13.24M | -11.95M | -12.34M | -11.34M | -15.49M | -16.31M | -17.26M | -14.88M | -19.53M | -25.74M | -13.96M | -10.79M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.54 | - | - | - | 0.25 | - | - | -0.51 | -0.64 | -0.42 | -0.44 | -0.44 | -0.46 | -0.29 | -0.22 | -0.20 | -0.23 | -0.23 | -0.23 | -0.17 | -0.22 | -0.26 | -0.14 | -0.11 |
| R&D Expense | 6.59M | 7.50M | 7.74M | - | 12.00M | 11.31M | 10.39M | - | 9.20M | 8.42M | 7.13M | - | 6.15M | 6.48M | 4.20M | - | 3.35M | 3.31M | 3.80M | - | 3.62M | 4.36M | 4.62M | 4.52M | 7.66M | 5.14M | 8.90M | 9.13M | 9.87M | 9.38M | 9.84M | 10.32M | 13.36M | 13.97M | 14.81M | 11.81M | 15.38M | 22.13M | - | 7.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 422.00K | 10.46M | - | 10.39M | 353.00K | 235.00K | 190.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 56.79M | 55.27M | 68.15M | 77.82M |
| Operating Income | -19.54M | -23.55M | -47.62M | -57.94M | -47.15M | -32.82M | -22.98M | -15.91M | - | -46.40M | -54.92M | -67.91M | -77.63M |
| EBITDA | - | - | - | - | - | - | - | - | - | -44.71M | -52.18M | -66.37M | -76.07M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | -45.34M | -50.40M | -64.02M | -74.12M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -20.01M | -24.35M | -47.97M | -57.85M | -48.21M | -34.52M | -16.22M | -16.22M | - | -45.34M | -50.39M | -64.02M | -74.12M |
| Diluted EPS | - | - | - | - | - | - | - | -1.77 | -1.77 | -1.60 | -0.94 | -0.86 | - |
| R&D Expense | 13.83M | 16.78M | 34.50M | 42.85M | 30.07M | 20.39M | 14.05M | 17.29M | 23.26M | 42.81M | 42.29M | 54.37M | 60.22M |
Compounded Sales Growth
| 5 Years: | -73.65% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -21.16% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -87.85% |
| 6 Months: | -29.20% |
| 3 Months: | -43.44% |
| 1 Month: | -29.02% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 20.64M | 129.68M | 80.52M | 89.36M | 52.75M | 36.19M | 38.73M | - | 95.79M | 120.65M | 96.83M | 93.00M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 80.87M | 102.99M | 81.95M | 80.24M |
| Cash & Equivalents | 3.67M | 36.46M | 13.90M | 53.02M | 38.39M | 21.09M | 22.96M | 9.21M | 16.95M | - | 9.98M | 22.54M | 11.05M | 10.74M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | 11.78M | 2.44M | 1.74M | 873.00K |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | 24.50M | 30.18M | 27.00M | 25.71M |
| Current Liabilities | - | - | 10.11M | 12.15M | 8.53M | 10.39M | 10.83M | 12.92M | 5.86M | - | 13.86M | 16.42M | 14.97M | 15.15M |
| Long Term Debt | - | - | - | 1.78M | 9.20M | 14.72M | 8.26M | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 11.53M | 15.10M | 13.28M | 12.03M |
| Total Equity | -64.55M | -66.08M | -91.01M | 115.05M | 62.80M | 64.25M | 33.65M | 21.19M | 31.65M | - | 71.46M | 90.66M | 70.02M | 67.48M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 29.50M | 63.29M | 84.04M | 98.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | -52.86M | -42.36M | -31.06M | -20.01M | -15.30M | - | -41.89M | -33.22M | -69.12M | -61.99M |
| Investing Cash Flow | - | - | - | 33.53M | -27.64M | 37.17M | 4.92M | 6.90M | - | 47.24M | -20.13M | 17.23M | -5.05M |
| Financing Cash Flow | - | - | - | 4.70M | 52.70M | -4.24M | 1.34M | 16.14M | - | 5.45M | 66.23M | 39.86M | 66.01M |
| Capital Expenditure | -644.00K | -249.00K | -664.00K | -600.00K | -1.31M | -594.00K | -79.00K | -202.00K | - | -1.64M | -4.21M | -65.00K | -77.00K |
| Free Cash Flow | - | - | - | -53.46M | -43.68M | -31.66M | -20.09M | -15.50M | - | -43.53M | -37.44M | -69.18M | -62.06M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 10.81M | 12.88M | -12.02M | -1.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | -5,445.0% | -152.2% | - | -446.8% | -15,557.8% | -28,899.6% | -40,856.3% |
| Net Margin % | - | - | - | - | - | - | -3,844.5% | -155.2% | - | -436.5% | -14,274.5% | -27,243.8% | -39,009.5% |
| ROE % | 30.3% | 26.8% | -41.7% | -92.1% | -75.0% | -102.6% | -76.6% | -51.3% | - | -63.4% | -55.6% | -91.4% | -109.8% |
| ROCE % | - | -223.7% | -40.5% | -80.5% | -59.7% | -78.3% | -98.8% | -48.4% | - | -56.6% | -52.7% | -83.0% | -99.7% |
Shareholding Pattern
Insiders
2.45%
Institutions
57.51%
Public Float
58.95%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | FMR, LLC | 15.00% | 14.71M | $7.98M |
| 2 | Federated Hermes, Inc. | 10.72% | 10.51M | $5.70M |
| 3 | Blackrock Inc. | 6.57% | 6.44M | $3.50M |
| 4 | UBS Group AG | 3.94% | 3.87M | $2.10M |
| 5 | Vanguard Capital Management LLC | 3.89% | 3.81M | $2.07M |
| 6 | Geode Capital Management, LLC | 2.43% | 2.39M | $1.29M |
| 7 | State Street Corporation | 1.79% | 1.75M | $951.76K |
| 8 | GSA Capital Partners LLP | 1.72% | 1.68M | $913.89K |
| 9 | Millennium Management Llc | 1.67% | 1.64M | $890.38K |
| 10 | Morgan Stanley | 1.25% | 1.23M | $664.82K |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ATYR
No recent headlines available.